# INTERVIEW: Deltex Medical Group Launch TrueVue system in US

- Link: https://www.directorstalkinterviews.com/interview-deltex-medical-group-launch-truevue-system-us/412738696
- Published: 2017-10-25T07:38:37+01:00
- Author: Giles Arbor

**Deltex Medical Group Plc** (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk
about the launch of it’s TrueVue system in the US. Ewan explains it’s functionality,
the situations it will be used for, what this means for Deltex and the benefits 
of attending the Anesthesiology 2017 conference in Boston this year.

 

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex
Medical’s proprietary ODM is the only technology to measure blood flow in the central
circulation in real time. Minimally invasive, easy to set up and quick to focus,
the technology generates a low-frequency ultrasound signal, which is highly sensitive
to changes in flow and measures them immediately. Deltex has been the only company
in the enhancedhaemodynamic space to build a robust and credible evidence base proving
the clinical and economic benefits of its core technology, ODM which is proven to
reduce complications suffered by patients after surgery and save hospitals the costs
of treating those complications.

 

Deltex Medical’s CardioQ-ODM+ platform also now provides clinicians with two further
advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography
is an entirely non-invasive monitoring technology which creates an electrical field
across the chest and measures the disruption to this field when the heart pumps 
blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis
to give doctors information on changes in the circulation and is particularly suited
to monitoring lower risk or haemodynamically stable patients.

Share on: